Trump administration’s challenge to Affordable Care Act casts shadow over biosimilars pathway

By requesting that the Supreme Court invalidate the entire Affordable Care Act, the Trump administration has put into play the biosimilars pathway and other parts of the law that are unrelated to core healthcare coverage provisions.

In a brief filed with the Supreme Court on June 25, the administration backed the position of Attorneys General of Texas and 17 other Republican-led states that the entire law must be struck down. ...